CBD Health

Cannabis is a genus of plants from the Cannabaceae family. Cannabis plants produce a unique family of terpenophenolic compounds called cannabinoids. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two cannabinoids that are usually most commonly produced, and only the former is psychoactive. The term hemp or industrial hemp usually refers to varieties with a low THC content (<0.3%). Hemp can be grown for many different purposes, be it for its seed, oil, food, and medicinal properties. [1] Certain hemp chemopreparations contain high levels of cannabidiol (CBD), the non-psychoactive phytocannabinoid that is of great interest because of its therapeutic potential for treating anxiety, cognition, movement disorders, and pain. [2] Hemp fibers are used in industry for a variety of purposes, including clothing, textiles, and cosmetics. For the past decade, hemp has been viewed as a potential source of biofuels with high conversion rates and yields: the hemp biomass can be fermented to produce low-carbon fuels such as bioethanol or biobutanol, while the oil obtained from hemp seeds is successfully converted into biodiesel through base-catalyzed transesterification. [3]

Hemp contains many phytocannabinoids in the aerobic part of the plant and CBD is usually the most abundant: through extraction processes, it is possible to isolate this valuable cannabinoid in the form of pure isolate or full-spectrum extract if the end product also contains other cannabinoids and phytonutrients. Unlike stems, leaves and flowers, hemp seeds do not contain phytocannabinoids and are used to obtain an oil with a rich profile of nutrients, fiber, vitamins, minerals and a high percentage of fatty acids, especially omega-6 and omega-3, optimal for human health. [4] It is possible to add plant material to the seed extraction as well, resulting in a full spectrum hemp oil with phytocannabinoids in the final extract.

References:

[1] Adesina, I. et al. An overview of the current state of knowledge about growing conditions, agronomic soil health practices, and uses of hemp in the United States. Agriculture, 10 (4), 129 (2020) doi: 10.3390 / agriculture10040129 [Times cited=  21]

[2] VanDolah, HJ et al. Clinician’s Guide to Cannabidiol and Hemp Oils. Mayo Clinic Procedure. (2019). doi: 10.1016 / j.mayocp.2019.01.003 [Journal impact factor= 6.942] [Times cited=  106]

[3] Si-YuLiet al. The feasibility of converting Cannabis sativa L. oil to biodiesel. , Bioresource Technology]101 (21), 8457-8460 (2010). doi: 10.1016 / j.biortech.2010.05.064 [Journal impact factor= 7.539] [Times cited=  75

 

[4] JC Callaway. Hemp seeds as a food source: an overview. , Euphytica 140 (1-2), 65-72. (2004) doi: 10.1007 / s10681-004-4811-6 [Journal impact factor= 1.614] [Times cited=  656]

picture: Hemp_Picture Sabina Pulone

The appointment of US President Joe Biden to a number of influential positions in the new administration gives cause for optimism in the hemp and cannabis sector.

While Biden himself appears to remain skeptical of recreational cannabis – having previously stated that it should be included in Appendix II of the Controlled Substances Act category – a wide range of key appointments appear to be solid proponents of hemp and cannabis.

Perhaps the most important appointment for CBD is the head of the Department of Health and Human Services (HHS). As the main government agency for Healthcare and consumer safety, HHS is responsible for several influential areas, such as: Food Products and new drugs through the Food and Drug Administration (FDA), implementing the country’s largest health programs (Medicare and Medicaid), and preventing the outbreak and spread of disease through the Centers for Disease Control and Prevention (CDC).

Xavier Becerra is the Biden candidate to lead the HHS. Former California Attorney General Becerra has considerable experience in helping cannabis reform and works to protect California’s legal program from federal interference.

Becerra was one of 21 attorneys general to write to congressional leaders to express their support for a bipartisan law to protect government cannabis programs from government interference.

And in an interview with the Los Angeles Times, he said, “Just as we allow alcohol to be sold, we have entered the 21st century and announced that it is better to regulate cannabis than criminalize it. There are far more important things to worry about than whether or not someone smokes cannabis for medicinal purposes. “

Becerra also spoke out strongly in favor of giving licensed cannabis companies access to the federal banking system. “The continued exclusion of the licensed cannabis industry from the federal banking system is untenable and unwise,” he said saidwhile serving as the California attorney general. “The coronavirus crisis has only exacerbated the economic and investigative challenges that arise from keeping a $ 15 billion industry in the shadows.

“Congress should pass these common sense laws quickly and provide relief to the many local cannabis companies who abide by the rules.”

Rachel Levine has been nominated as Assistant Secretary to HHS and, if confirmed, will bring a wealth of political expertise on medical cannabis – an essential requirement given the strong support medical cannabis enjoys in the new administration, with even Biden expressing his support .

The American Trade Association of Cannabis and Hemp (ATACH) called her “a pioneer who successfully led the implementation of Pennsylvania’s medical cannabis program.” It added, “Pennsylvania is now one of the fastest growing and most momentous medical marijuana markets in the country, in large part due to the work of Dr. Levine. “

Federal medical cannabis policy will be of concern to a large portion of the US population.

Under Levine, the Pennsylvania Department of Health oversaw temporary changes to the state’s medical cannabis program in response to the coronavirus pandemic. This included removing restrictions on the number of patients a registered nurse can work with.

“In the midst of Covid-19, we need to ensure that medical marijuana patients have access to medicines,” she said. “We want to ensure that medical marijuana program cardholders can get medication for one of 23 serious medical conditions during this difficult time.”

Presumably Levine would carry that enthusiasm into her new role at the federal level.

While the HHS will play an important role in how the Biden administration handles the medical and scientific aspects of the policy, the Department of Justice will play a critical role in regulating and enforcing cannabis and hemp. The Biden candidate to head the department is Merrick Garland, a name known to then-President Barack Obama as a candidate for the Supreme Court and who was denied a hearing by then Senate Majority Leader Mitch McConnell.

Biden has hired Garland to lead a demoralized department that has been ravaged by four years of attrition at all levels and unprecedented partisanship. Garland has a reputation for being a smart and sincere manager, but hasn’t made his views on cannabis issues particularly clear.

His court record shows that he has respect for the Drug Enforcement Administration (DEA) when it comes to drug planning, a key aspect of how cannabis is viewed by the federal government.

Some in the industry have criticized him for this approach, saying that it is overall negative for the future of cannabinoid regulation.

The DEA, based in the Justice Department, has repeatedly claimed that cannabis should be kept as a List I drug because the plant has no proven medicinal value and high risk.

Garland’s ruling as a judge on the appellate court in a 2012 federal lawsuit over the DEA’s rejection of a marijuana rescheduling suggests that he believes it is the appropriate authority to weigh cannabis science and establish a scheduling policy.

“Don’t we have to submit to the authorities when it comes to evaluating research into the therapeutic value of marijuana?” Garland asked the attorney who represents the Americans in the reform group for safe access. “Procrastination doesn’t mean they win. But sit back in the sense that we are not scientists – they are – the definition of an adequate and well-controlled study. “

But these comments have to be seen in context. Garland requested this from a lawyer serving as a judge during an oral hearing. The use of the term “postponement” in relation to a federal authority differs slightly from postponement in common parlance.

A judge’s job is to evaluate the evidence presented and determine the credibility and weight that should be placed on it. As a judge evaluating evidence, it is customary to submit to experts on a scientific subject. The role of the Justice Department chief is very different, however, and Garland will be able to influence, if not dictate, the policies and positions of the DEA.

In essence, as the head of the department under which the DEA is organized, the Attorney General has significant influence on the agency’s planning and enforcement policy. If confirmed, Garland would be able to essentially order a postponement of cannabis.

And there is greater potential for reform among his subordinates. One of his key deputies in the Justice Department would be Vanita Gupta, a former prosecutor and civil rights activist who advocated the legalization of cannabis and strongly condemned the harsh policies of criminalizing nonviolent drug offenses.

Gupta currently serves as President of the Leadership Conference on Civil and Human Rights (LCCHR) and has spoken out in favor of a House of Representatives bill to legalize state cannabis. She also voted against the injustices of the drug war.

In the meantime, a lot of positive things have already happened in the field of hemp in agriculture. Biden has nominated Tom Vilsack to return to his role as Minister of Agriculture, a position he held every eight years of the Obama presidency.

Under Vilsack’s leadership of the U.S. Department of Agriculture (UDSA), the 2014 Farm Bill, which included the hemp pilot program, was passed.

Jonathan Miller of the US Hemp Roundtable named Vilsack a “longtime champion in hemp,” adding, “We are incredibly optimistic that he will help provide the guidance and clarity needed to create opportunities in the hemp industry. “

Such a champion leaves open the slim possibility of further positive revisions to the final USDA rule for hemp production.

The White House issued a memo in late January 2021 urging agencies to withdraw or pause any rules that have not yet been published in the federal register to give the new administration time to review.

The USDA said CBD intelligence: “The new government is taking this opportunity to review new and pending regulatory actions, including the final settlement for the Domestic Hemp Production Program, to ensure that the programs are structured and adequately resourced, and to ensure that the programs implemented in such a way that they best serve the intended stakeholders. Once the review is complete, we will have more information on how to proceed with the rule. “

What that means: Apparently positive dates all around. Even Merrick Garland’s nomination to head the Department of Justice can be seen as positive for most cannabinoids, and even likely positive for the recreational cannabis end of the market.

Significant medical cannabis and CBD support is likely to come from the HHS, and while key appointments with the FDA and DEA are still pending, optimism is about to emerge Federal cannabis legalization during this legislative period.

Although this is still in the extreme range of what is realistically achievable, it is still a long way from the uncertainty and pessimism of recent times.

It looks like Joe Biden is on a pro-cannabis democrat train whether he really wants it or not.

CBD intelligence (www.CBD-Intel.com) provides impartial, independent and world-class market and regulatory analysis, law enforcement and quantitative data for the cannabidiol (CBD) sector.

We offer our clients the tools to navigate this fast-moving sector, adjust their business strategy, optimize resources and make informed decisions. In addition, we offer tailor-made research and advice support.

CBD companies continue to make advances in the health and wellness subcategory with new product launches, distribution agreements, and ongoing clinical trials.

California-based CBD product maker CV Sciences has announced the launch of a full line of clinical-strength CBD products available only from doctors in the United States.

The company said the products will be backed by published research, randomized controlled trials, and a post-market safety review. It added that they are designed to fit into existing care plans and are available in roll-on, liquid and softgel formulations.

“Alternative medicine use is becoming more common as consumer preferences shift towards natural, herbal remedies for a range of conditions. We are excited to bring ProCBD to market and to partner with health professionals who are seeking science-based, natural alternatives for their patients, “said Joseph Dowling, CEO of CV Sciences.

Similarly, Canadian nutraceutical company NeutriSci International has focused on the health and wellness market. It said it intends to launch its broadband CBD tablet brand Tabletz in Japan.

The company plans to manufacture and distribute several hundred thousand units of the tablet sticks in a number of retail locations in Japan, where, according to NeutriSci, consumers are strong advocates of plant-based health and wellness products. The company said it hadn’t finalized the details of in-store distribution, but previously listed 7-Eleven, KK Lawson and Biople as potential Japanese retailers.

“We believe we can reach a significant share of the CBD market in Japan. There is currently no comparable product on the market, ”said Glen Rehman, CEO of NeutriSci.

The product is now waiting in the port of entry for customs classification (HS code). It is sold in three and seven tab sticks and comes in three flavors – lemon, berry, and mint.

“With product approvals, a pause in new application approvals at the ministerial level, combined with the features and benefits of the product itself, plus a strong distribution network and positive initial consumer feedback, there is strong confidence that Tabletz can do one of the best-selling CBD brands of its kind in Japan be, ”said Rehman.

NeutriSci is also working on the upcoming launch of a large bottle format (35 14 mg tablets totaling 490 mg CBD) from Tabletz, which will also be available in the same three flavors and is expected to be part of a second order for the Japanese market.

The company had previously announced that it would officially launch the Tabletz brand in the Japanese market in November 2020, but this has been delayed for reasons that are currently unclear. It just completed a round of funding that sold nearly 2.5 million shares at $ 0.15 each to raise $ 370,050 to be used for production runs related to its product launch in Japan.

And in Europe, UK health and wellness chain Holland & Barrett has signed distribution agreements with European manufacturer of CBD and hemp oil products, Reakiro, and has expanded its ongoing distribution relationship with World High Life’s Love Hemp brand.

Reakiro’s range of full spectrum products includes oils, sprays, a raw hemp extract pen and gelcaps in a wide range of strengths and will appear in all 737 UK stores and online.

“We are very proud to partner with Holland & Barrett, the leading health and wellness retailer,” said Stuart McKenzie, CEO of Reakiro. “Holland & Barrett and Reakiro share the same values ​​- providing the highest quality natural health products to people around the world. We look forward to a productive and long-term partnership with you. “

Love Hemp has launched another ten products, including sprays and capsules, in 880 Holland & Barrett stores in the UK and Ireland and made the products available through the health food store’s website. These include various strengths from 600 mg to 3,000 mg of CBD.

Love Hemp and Holland & Barrett have also launched a consumer education and awareness program on CBD in 400 of their stores to help build consumer knowledge about the benefits of CBD. It is unclear what paid agents could say who did not violate the ban on marketing health claims.

“This is a significant relationship not only in terms of scale, but also because Love Hemp and Holland & Barrett implemented a groundbreaking education and awareness program designed to educate consumers about the benefits of CBD,” said Tony Calamita, CEO by Love Hemp. “It is important to invest with partners like Holland & Barrett to build consumer knowledge and confidence so that they know they are buying credible products from credible retailers.”

Meanwhile, the Australian company Avecho Biotechnology has joined a medical cannabis study that, if successful, could open up the range of CBD products on the market and increase their therapeutic potential.

The CA Clinics Observational Study (CACOS) will, for the first time, test the performance of Avecho’s oral CBD formulation on human patients to continue previous successful demonstrations of the product’s ability to aid the absorption of CBD drugs in animals.

“This study is an important step in gathering real-world evidence from patients,” said Paul Gavin, CEO of Avecho. “The entry into an existing test framework offers Avecho both cost and speed advantages.”

If the product’s effectiveness is demonstrated in human patients, Avecho believes it could create room for more CBD products on the market at lower cost and with greater therapeutic potential.

“The design of the observational study enables the product to be used in a range of indications that may prioritize certain indications for further development or eliminate indications where treatment is less effective,” said Gavin.

The company will use the study to gather feedback on the performance of the product from patients currently using medical cannabis to treat a range of indications. Performance is compared to commonly prescribed CBD formulations.

The CACOS study aims to recruit 3,000 patients through a network of medical cannabis prescribing clinics and will use questionnaires to examine the side effects, dosage response and treatment satisfaction of medical cannabis formulations on patient health.

The data generated will help shape the future development of Avecho’s pharmaceutical CBD products while also exploring the potential for Australian SAS-B prescribing.

Recruitment for the CACOS trial will begin immediately and will last through 2021.

CBD intelligence provides impartial, independent and world-class market and regulatory analysis, law enforcement and quantitative data for the cannabidiol (CBD) sector worldwide.

We offer our clients the tools to navigate this fast-moving sector, adjust their business strategy, optimize resources and make informed decisions. In addition, we offer tailor-made research and consulting support.

Cannabidiol (CBD) has a pretty good reputation for its anti-anxiety effects, but does CBD really help with anxiety? Research on CBD from hemp has been less limited than CBD from cannabis, and even CBD from cannabis has been studied more closely in recent years. A lot of scientific evidence has accumulated over time suggesting that CBD may help some people with anxiety, although it varies from person to person.

As early as 2015, the National Institute on Drug Abuse reported CBD has several medicinal benefits. These included anti-anxiety effects, based on several scientific findings showing the safety and effectiveness of CBD in treating a range of symptoms related to anxiety and stress. It was also mentioned that “the anxiety-reducing effects of CBD appear to be mediated through changes in serotonin receptor 1a signaling,” suggesting that more research is needed to determine the exact mechanisms that trigger these anxiety-reducing responses. [1]

This call for more research seemed to skip over at the time research which was published in 2010. Scientists in Brazil examined the neural basis of the anxiolytic effects of CBD in generalized anxiety (SAD). Their research concluded that CBD “significantly reduced subjective anxiety” and recommends CBD for reducing anxiety in people diagnosed with SAD. It should also be noted that the effective dose for the anti-anxiety effects was 400 mg of CBD. [2]

While these research results sound promising, cannabinoid medicine is still a very individual process, which means that it can vary from person to person due to our unique biological makeup. A study The study, published earlier this year, looked at a possible placebo effect if patients are already firmly convinced of the effectiveness of CBD in reducing anxiety. They confirmed that the expected results from CBD influenced many of the participants’ subjective and physiological responses, including anxiolytic effects. [3] CBD seems to help several people with varying levels of anxiety and symptoms, but these types of pointers to keep in mind when wondering whether CBD can help with your anxiety.

References:

1 – Volkow, N. The biology and potential therapeutic effects of cannabidiol. National Institute on Drug Abuse. 2015. https://archives.drugabuse.gov/testimonies/2015/biology-potential-therapeutic-effects-cannabidiol

2 – Crippa, J. et al., Neural Basis of the Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: A Preliminary Report. Journal of Psychopharmacology. 2010. https://journals.sagepub.com/doi/10.1177/0269881110379283

3 – Spinella, T. et al., Evaluation of the anticipatory effects of cannabidiol (CBD) on acute stress and anxiety in healthy adults: a randomized crossover study. Psychopharmacology (Berl). 2021 Jul; 238 (7): 1965-1977. https://pubmed.ncbi.nlm.nih.gov/33813611/

With the rise of the cannabis and hemp industries in recent years, cannabidiol (CBD) is now at least vaguely known to everyone. Most people have at least heard the term, and many have seen it on shelves from local cafes to mainstream health stores like Walgreens. Wherever you’ve seen or heard of CBD, there is a good chance you are aware that it is touted for several medical benefits that help with conditions such as pain, inflammation, various forms of epilepsy, and many others. According to a national survey, 14% of Americans admit consuming CBD products, with 40% reporting pain, 20% reporting anxiety, and 11% reporting sleep. [1]

With so many people reporting the medicinal benefits of CBD, it calls into question the psychological effects of CBD. Thanks to the legalization of cannabis and hemp in the United States, restrictions on research into cannabinoids like CBD are further relaxed, giving way to new and important research. In 2020, a systematic review was published that analyzes the available clinical research on CBD for use in various medical and psychiatric conditions and provides several promising results.

When compared, for example, with anxiety, the review found that CBD decreased neurons that cause anxiety, “and infusing CBD directly into the amygdala neurons resulted in decreased anxiety-related behavior”. For those suffering from other psychological conditions like PTSD, a small study mentioned in the review found that “ninety-one percent of patients reported a decrease in nightmare symptoms” after being given oral CBD. [2]

The psychological relationship between CBD and depression also looks positive, with animal models showing a “significant antidepressant-like effect after administration of CBD”. Human studies found that “CBD is a microglial stabilizer in vitro that is similar to the drug lithium that may be beneficial for depression and mood stabilization.” [2]

Even when compared to more intense psychological conditions such as psychosis, especially in schizophrenia, the review says, “In studies of animal models of schizophrenia, CBD has shown that it improves psychotic symptoms.” [2]

All of these pointers are promising indicators that CBD has positive psychological effects, but keep in mind that each person’s biological makeup is extremely unique. The differences between one person’s neurological and mental health to another are extremely individual. This makes your unique properties very important when deciding whether or not CBD can have the same positive psychological effects as the literature discussed.

References:

1 – Brenan, M. 14% of Americans say they use CBD products. Gallup poll. 2019. https://news.gallup.com/poll/263147/americans-say-cbd-products.aspx

2 – Oberbarnscheidt, T., et al., The Influence of Cannabidiol on Psychiatric and Medical Disorders. Journal of clinical medical research. 2020 July; 12 (7): 393-403. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331870/

First off, what is CBC? CBC is a minor cannabinoid called cannabichromene (CBC). Being a minor cannabinoid is one of the reasons we don’t hear much about CBC. It is not found in very high percentages compared to other major cannabinoids such as cannabidiol (CBD). This can make the extraction costly, which is another reason you don’t hear much about it, but you should because CBC has many benefits and uses as a medicine.

The anti-inflammatory effects of CBC are of great benefit to people with pain and other ailments caused by inflammation, as well as people with autoimmune diseases that cause increased inflammation and several other inflammatory conditions. One study directly examined the pharmacological potential of CBC and found that CBC was effective “dose-dependent” anti-inflammatory effect“. [1]

Another study, published in Neurochemistry International, discovered that CBC was an excellent cannabinoid for brain health. It was even compared to CBD and CBG, and the results showed that CBC has beneficial effects on neural stem progenitor cells. These cells are essential for healthy brain function, and CBC increased their viability, making CBC a potential candidate for treating disorders related to brain cells and brain health. [2]

If that’s not enough to talk about CBC, what if you found out that CBC was shown to be effective in treating cancer? So effective in fact research Studying the effectiveness of several cannabinoids on anti-tumor activity in breast cancer may have found that CBD is the most effective at inhibiting tumor growth, but CBC came right behind it. This means that CBC can help stop tumors from growing. Maybe not as much as CBD, but enough to take second place. [3]

Despite these and many other medicinal benefits of CBC, there is a good chance it will take a back seat to better-known cannabinoids like CBD for the time being. As the science of cannabinoid medicine advances, other cannabinoids like CBC will gain ground to be better recognized and discussed as more of their true potential is discovered.

References:

1- DeLong, G., et al., Pharmacological Evaluation of the Natural Ingredient of Cannabis sativa, Cannabichromene and its modulation by Δ⁹-Tetrahydrocannabinol. Drug and alcohol addiction. 2010. 112, (1-2) 126-133. https://www.sciencedirect.com/science/article/abs/pii/S0376871610002073

2- Shinjyo, N., et al., The Effect of Cannabichromes on Adult Neural Stem / Progenitor Cells. Neurochemistry International. 2013. 63. (5) 432-437. https://www.sciencedirect.com/science/article/abs/pii/S0197018613002106

3- Ligresti, A. et al., Antitumor Activity of Plant Cannabinoids, Emphasizing the Effect of Cannabidiol on Human Breast Cancer. Journal of Pharmacology and Experimental Therapeutics. 318 (3) 1375-1387. https://jpet.aspetjournals.org/content/318/3/1375.long

Testing has become a fundamental part of the cannabis industry. Laboratories have sprung up across the country to provide testing services to the hundreds of companies that now exist in this fast growing industry. One of the most important things these labs test for is the presence and concentration of cannabinoids, both large and small, using a variety of high-tech tools and equipment.

Several Dozens of cannabinoids found in cannabis. However, not all of them are that valuable to the cannabis industry, at least not yet. Currently, the most valuable cannabinoids are tetrahydrocannabinol (THC) and cannabidiol (CBD), which are known as the most important cannabinoids.

As the industry matures and research continues, other cannabinoids are known as the smaller cannabinoids, can prove to be just as valuable as THC and CBD. These other cannabinoids of interest currently include tetrahydrocannabinolic acid (THCA), tetrahydrocannabivarin (THCV), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), and cannabichromene (CBC). When speaking of these minor cannabinoids, it is important to understand that the term “inferior” does not refer to the effect these cannabinoids have on their users. Rather, the term “minor” refers to their concentrations in cannabis plants – the main cannabinoids are more abundant than the smaller ones, hence the terminology.

When labs test for cannabinoids, they use two principles Test methods: Ultra High-Performance Liquid Chromatography (HPLC) and Gas Chromatography (GC). Both tests tell you what cannabinoids are in a sample and also show you how concentrated they are in the sample.

However, both tests are not the same. In fact, HPLC is often the preferred test when handling cannabis and cannabinoids because it is a test method that can be done at room temperature. While GC tests require a heat catalyst to trigger a reaction in the sample to detect cannabinoids present. This heat catalyst prevents GC tests from detecting the cannabinoids THCA and CBDA, which turn into THC and CBD when heated. In other words, HPLC is a more comprehensive test for cannabinoids.

Image source: https://www.pexels.com/photo/set-of-glass-tube-in-laboratory-4021793/

Projections of Statista estimate that cannabidiol (CBD) sales will grow to $ 1.8 billion by 2022, up from just under $ 0.5 billion in 2018. If you’re an investor looking to weather this wave, here’s a breakdown of the top CBD products made from the Shelves have flown.

CBD gummies

CBD gummies remain an all-time favorite for busy mothers who want to incorporate delicious CBD treats into their everyday lives. Gummies are available in sizeable doses such as 5 mg, 10 mg, and 20 mg, which make dosing easier. They don’t require any special skills or tools to consume. All you have to do is toss a gummy bear or two in your mouth and wash it down with your favorite beverage. Compared to capsules, gummy bears come in brightly colored and delicious variants and are therefore more attractive. If you need to offer kids CBD, gummy bears are the way to go. It’s no surprise that they are among the top-selling CBD products.

Some of the best-selling CBD gums on the market include the Lord Jones gummy candies, which have lemon and strawberry flavors and contain 20 mg of broad spectrum CBD.

CBD vapes

Vaping is a pretty nifty way of consuming CBD. Manufacturers have worked hard to grab the attention of the younger population by making cheeky vaporizers in a variety of flavors. Like e-cigarettes, vaporizers deliver CBD to the lungs quickly; Blood peaks occur after about 10 minutes and the effects can last for up to 3 hours. This makes vaping an ideal way to relieve anxiety in high pressure situations.

The safety of CBD vapes was approved in 2019 following the Steam crisis. This, of course, affected sales of CBD vapes. However, there was a rebound in sales following analytical reports that the steam crisis was due to contamination with vitamin A acetate. Manufacturers who can determine the safety of the CBD vapes can continue to enjoy dominance in the market. Some of the most popular CBD vapes on the market are the artisanal CBD vape pens from Secret Nature and the exquisite vape pens from Funky Farms.

subjects

This is a highly diversified product category that has taken the skin care market by storm. Skin care manufacturers are rushing to add CBD to their product repertoire for its purported skin benefits. The best-selling CBD skin care products containing CBD include bath bombs, lotions, creams, ointments, and patches, among others. Topicals are applied directly to the skin and are easily absorbed by the numerous endocannabinoid receptors located there. They have wide appeal because they are effective in fighting skin diseases.

What’s in the future?

We expect product inventions and diversification in the CBD sector. The fierce competition in the market will force manufacturers to be more resourceful when it comes to product development. It will be interesting to see how this space evolves in 2021 and 2022 as we get closer to the $ 1.8 billion mark.

Image source

https://pixabay.com/id/vectors/best-seller-penjual-cap-merah-158885/

While you can include cannabidiol (CBD) in your daily intake at any time by placing a drop under your tongue or vaping it, you can also take advantage of its healing properties while enjoying a meal or a sweet treat.

CBD can easily be added to some of your favorite recipes and enjoyed as a homemade edible, but there are a few basic rules that you must follow to get the most of cooking with CBD oil.

Consider the serving size

Make sure you factor in the serving size of the dish you are preparing or the batch of baked goods you bake so that the CBD concentration is sufficient to achieve the desired dosage. For example, if you want 20 mg of CBD in every cookie you make from a batch of 24, you need about 480 mg of CBD added to the entire batter. Adjust this based on the serving size and the exact dosage you are looking for per serving.

Do not cook over high heat

Overheating the CBD could destroy the active ingredients in the cannabinoid and make it less effective. When heating the oil on the stove do not keep the burner higher than medium. And when you bake, try not to set your oven above 350 ° F. Otherwise, the CBD could evaporate.

If possible, add the CBD oil to your dish after cooking. Otherwise, be careful how hot you turn up the heat on your stove or oven when cooking or baking directly with CBD.

Keep the taste in mind

Many CBD tinctures tend to have a bitter taste, so you might want to add some flavor to make it tastier. However, many other CBD products have different flavors that are reminiscent of berries, honey, citrus fruits, mint, etc.

When choosing a CBD oil, keep in mind the dish you plan to prepare as the flavors may not mix as well as you would like. It may take a little experimentation before you get it just right and create perfect flavor combinations.

Use a fat base

CBD works quite well when the recipe includes a healthy fat, such as coconut oil, olive oil, ghee, or butter. Because of this, CBD oil is perfect for baking and cooking. You may even want to mix your CBD with the fat you use in your recipe before mixing it with the rest of the ingredients.

Image source: Galina Afanaseva from Pixabay